Kerem Batsheva, HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences

Company Profile

Splisense is developing targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease.


SpliSense’s initial focus is on Cystic Fibrosis. SpliSense is developing a new class of therapies which treat the underlying genetic cause of the disease, leading to the production of a normal protein.

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: